StemCells (STEM) Recieves Approval for Stem Cell Trial for Patients with Spinal Cord Injuries
Tweet Send to a Friend
StemCells, Inc. (Nasdaq: STEM) announced Tuesday that it has received authorization from Swissmedic to start a Phase I/II trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
